Physician profile
Drew W Charles
NPI 1972064715
$2,471.83
in general payments reported to CMS, 2019-2025
9 companies · $240 in 2025
The $240 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $236 · 2023: $805 · 2024: $1,191 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,235.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $971.16 | 2022-2024 | Epclusa |
| Abbvie INC. | $367.23 | 2024 | |
| Daiichi Sankyo INC. | $246.14 | 2024-2025 | Vanflyta |
| Shionogi INC | $241.11 | 2022-2023 | Fetroja |
| Jazz Pharmaceuticals INC. | $144.72 | 2024 | |
| La Jolla Pharmaceutical Company | $142.82 | 2024 | Xerava, Xacduro |
| Insmed, INC. | $120.33 | 2023 | Arikayce |
| Melinta Therapeutics, LLC | $119.25 | 2025 | Rezzayo |
| Takeda Pharmaceuticals U.S.A., INC. | $119.07 | 2023 | Livtencity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Charles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.